Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




AI Identifies Severe Aortic Stenosis from Routine ECGs

By HospiMedica International staff writers
Posted on 02 Sep 2022

Aortic stenosis is the most common primary valve lesion requiring surgery or transcatheter intervention in Europe and North America. More...

Prevalence is rapidly increasing due to ageing populations. Guidelines strongly advise early intervention in all symptomatic patients with severe aortic stenosis due to the dismal prognosis. Approximately 50% of untreated patients with aortic stenosis die in the first two years after symptoms appear. Echocardiography is used to assess severity, namely with peak velocity, mean pressure gradient and aortic valve area. However, there is increasing evidence that elevated mortality risk extends beyond current diagnostic definitions and more patients should be considered for aortic valve replacement. Now, a novel artificial intelligence (AI) algorithm uses routine echocardiograms to identify aortic stenosis patients at high risk of death who could benefit from treatment.

Researchers at the University of Notre Dame, Australia (Fremantle, Australia) examined whether an AI algorithm developed from echocardiographic parameters routinely used in clinical practice could identify moderate-to-severe and severe aortic stenosis phenotypes associated with increasing five-year mortality. The proprietary AI-Decision Support Algorithm (AI-DSA) used was trained using data from the National Echo Database of Australia (NEDA), which contains more than 1,000,000 echocardiograms from over 630,000 patients and is linked to mortality information. The algorithm was also trained to ensure all guideline-defined severe aortic stenosis was detected. Training was performed using 70% of the NEDA data, which were randomly selected.

Using the remaining 30% of NEDA data, the researchers compared five-year death rates in patients with the moderate-to-severe and severe aortic stenosis phenotypes with five-year death rates in patients without significant risk of severe aortic stenosis. Out of 179,054 individuals, the AI-DSA identified 2,606 (1.4%) with a moderate-to-severe phenotype and 4,622 (2.5%) with a severe phenotype. Of those with a severe phenotype, 3,566 (77.2%) met guideline criteria for severe aortic stenosis.

The five-year mortality rate was 56.2% in patients with the moderate-to-severe phenotype and 67.9% in those with the severe phenotype. Those without either phenotype (the reference group) had a 22.9% five-year mortality rate. Compared with the reference group, the age- and sex- adjusted odds ratio (OR) for all-cause mortality was 1.82 (95% confidence interval [CI] 1.63–2.02) and 2.80 (95% CI 2.57–3.06) for patients with the moderate-to-severe and severe phenotypes, respectively. Within the severe aortic stenosis phenotype identified by the AI-DSA (4,622; 2.5%), those that met current guidelines (77%) had a five-year mortality of 69.1%. The additional population identified by the AI-DSA with a severe phenotype, but who do not meet current guidelines, had a mortality rate of 64.4%.

“This proprietary AI algorithm picks up patients with a high risk (and all patients within current guidelines) of dying within five years that may be missed by conventional definitions. The findings suggest that the AI algorithm could be used in clinical practice to alert physicians to patients who should undergo further investigations to determine if they qualify for aortic valve replacement,” said principal investigator Professor Geoffrey Strange of the University of Notre Dame, Australia. “Given the rising prevalence of aortic stenosis and its impact on mortality, it is time to revisit the practice of watchful waiting and consider more proactive attempts to identify those at risk. More research is needed to determine if aortic valve replacement improves survival and quality of life in patients identified by the AI-DSA as having a high risk of mortality, but who do not meet current guideline definitions.”

Related Links:
University of Notre Dame, Australia 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.